Contact Us

    • 1-631-466-5530
      44-207-097-1828
    • 1-631-207-8356
    • 45-1 Ramsey Road, Shirley, NY 11967, USA
    • Global Locations

Oncolytic Viruses in Bladder Cancer Treatment

Introduction of Bladder Cancer

Bladder cancer is a disease in which malignancy forms in the tissues of the bladder. There are three types of bladder cancer that begin in cells in the lining of the bladder. These cancers are named for the type of cells that become malignant (cancerous): transitional cell carcinoma (TCC), squamous cell carcinoma and adenocarcinoma. Approximately, 85% of patients with bladder cancer have tumors that are limited to the mucosa of the bladder or penetrate the submucosa (stage T1). These superficial bladder cancers are now being described as non-muscle-invasive bladder cancer (NMIBC), with which approximately 70-80% are stage Ta, 20% are T1, and 10% are CIS. In recent years, the treatment of NMIBC has been greatly improved. Recommended treatment for patients with these high-grade tumors is transurethral resection followed by intravesical treatment with the immunotherapeutic agent Bacillus Calmette-Guérin (BCG) and immunotherapy. However, there is a need for other bladder-sparing treatment options when patients fail BCG and chemotherapeutic agents.

Oncolytic Viruses in Bladder Cancer Treatment

Oncolytic Viruses for the Treatment of Bladder Cancer

As a clinical setting in which local live biological therapy is already well established, bladder cancer presents intriguing opportunities for oncolytic virotherapy. Bladder cancer is an ideal target for the evaluation of local oncolytic viral therapy for several reasons, including easy intravesical instillation allowing the tumor to be exposed to large titers of vector, limited systemic exposure and papillary configuration increasing surface area for topical application.

Oncolytic Viruses in Bladder Cancer Treatment

Despite the encouraging results of preclinical and early clinical results, the ultimate proof of antitumor efficacy and safety still needs to be provided by randomized phase III clinical trials. Thus, the potentially high degree of safety and efficacy predicted for oncolytic virus therapy of cancer warrants immediate further investigation at both preclinical and clinical levels. With years of research in virotherapy, by integrating the technologies of viral biology, immunology and genetic engineering, Creative Biolabs has established an OncoVirapy™ platform for Oncolytic virus design, engineering, validation and manufacture.

Reference

  1. Potts, K.G.; et al. Oncolytic viruses in the treatment of bladder cancer. Advances in urology. 2012.

Please feel free to contact us for a quote and further discussion with our scientists.

All services and products are for lab research only, not for any clinical use.

Online Inquiry

  • Verification code
    Click image to refresh the verification code.

Contact Us

  • 1-631-466-5530
    44-207-097-1828
  • 1-631-207-8356

Contact Us

Copyright © 2007 - 2021 Creative Biolabs. All Rights Reserved